glp-1 obesity drug news today october 2025 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for treatment as of 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC pharma news today obesity drugs

Eisenberg T, Knauer H, Schauer A, Bttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, Fussi H, Deszcz L, Hartl R, Schraml E, Criollo A, Megalou E, Weiskopf D, Laun P, Heeren G, Breitenbach M, Grubeck-Loebenstein B, Herker E, Fahrenkrog B, Frhlich KU, Sinner F, Tavernarakis N, Minois N, Kroemer G, Madeo F (2009) Induction of autophagy by spermidine promotes longevity

Secretary Kennedy has now talked about descheduling testosterone, about legalizing some peptides

If you would like a personalized evaluation of your symptoms and options, request a consultation below

Dual GLP-1 / GIP Receptor Agonist (CAS 2023788-19-2) Compound Name: Research Peptide (CAS 2023788-19-2) Classification: Research Peptide Multi-Receptor Agonist Description: This compound is a synthetic research peptide that functions as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucose dependent insulinotropic polypeptide receptor (GIPR)

The precision approach to peptide dosing for weight loss requires attention to timing, titration, cycling, and individual response monitoring